Key result
Higher HDL-C linked to ~68% lower CAD risk in Native Hawaiians and Pacific Islanders.
Why the study?
Cardiometabolic diseases are especially prevalent in Native Hawaiians and Pacific Islanders, but the association of HDL-C with CAD, MACE, and T2D in this population compared to the general population was uncharacterized.
Does HDL-C have a stronger protective association against cardiometabolic diseases in Native Hawaiians and Pacific Islanders compared to the general population?
Cohort (n=189,063)
Yes
Does HDL-C have a stronger protective association against cardiometabolic diseases in Native Hawaiians and Pacific Islanders compared to the general population?
Effect estimate: HR 0.32 (95% CI 0.19-0.54)
HDL-C exhibits a significantly stronger protective association against coronary artery disease in Native Hawaiians and Pacific Islanders compared to the general population.
BACKGROUND: High-density lipoprotein cholesterol (HDL-C) is inversely associated with cardiometabolic risk and exhibits nonlinear effects at extreme levels. Cardiometabolic diseases are a leading cause of death and are particularly prevalent among Native Hawaiian and Pacific Islanders (NHPIs). OBJECTIVES: This study characterizes HDL-C's association with coronary artery disease (CAD), major adverse cardiovascular events (MACE), and type 2 diabetes (T2D) in NHPIs compared to the general population. METHODS: Using electronic health record data from the National Institutes of Health All of Us Research Program, we applied Cox proportional hazards models to compare HDL-C's protective effects on CAD, MACE, and T2D between 261 NHPIs and the remaining cohort (n = 188,802). Models were adjusted for key confounders, and restricted cubic splines were used to assess nonlinear risk dynamics. RESULTS: Tracking individuals across 10,534,661 person-years (mean age 55.7 ± 15.8 years, 38% male), HDL-C was more strongly associated with reduced CAD risk in NHPIs (HR: 0.32; 95% CI: 0.19-0.54) than in the general cohort (HR: 0.57; 95% CI: 0.56-0.58). A marginally stronger association was observed for MACE (NHPI HR: 0.40; 95% CI: 0.23-0.71 vs general HR: = 0.54; 95% CI: 0.53-0.56), while T2D associations were similar. Spline analysis indicated that low HDL-C increases risk for both CAD and T2D in NHPIs. CONCLUSIONS: HDL-C's protective role against cardiometabolic diseases is more pronounced in NHPIs, particularly for CAD. These findings support further investigation into tailored clinical assessments for this population.
No takes yet. Share an insight, caveat, or question.
Szatrowski et al. (2025) conducted a cohort in Coronary artery disease, major adverse cardiovascular events, and type 2 diabetes (n=189,063). High-density lipoprotein cholesterol (HDL-C) vs. General population was evaluated on Coronary artery disease (CAD) (HR 0.32, 95% CI 0.19-0.54). Higher HDL-C was more strongly associated with reduced coronary artery disease risk in Native Hawaiians and Pacific Islanders (HR 0.32; 95% CI 0.19-0.54) than in the general cohort (HR 0.57).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: